Karin P M van Galen
Overview
Explore the profile of Karin P M van Galen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
ODonnell M, Abdul Kadir R, van Galen K, Lavin M
Haemophilia
. 2025 Feb;
PMID: 39917900
No abstract available.
2.
van Kwawegen C, Fijnvandraat K, Kruip M, de Meris J, Schols S, Meijer K, et al.
Haemophilia
. 2024 Oct;
30(6):1348-1356.
PMID: 39403864
Introduction: The severity of Von Willebrand disease (VWD) is currently based on laboratory phenotype. However, little is known about the severity of the patient's experience with the disease. The most...
3.
van Kwawegen C, Atiq F, Endenburg D, Fijnvandraat K, van Galen K, Cnossen M, et al.
J Thromb Haemost
. 2024 Sep;
22(12):3460-3472.
PMID: 39343102
Background: Type 2B von Willebrand disease (VWD) is a bleeding disorder caused by gain-of-function variants in the VWF gene. The laboratory and clinical phenotype of type 2B VWD is heterogeneous....
4.
Kuppens G, Fischer K, van Galen K, van Beers E, Van der Valk P, Kremer Hovinga I, et al.
Haemophilia
. 2024 Jul;
30(5):1148-1154.
PMID: 39010315
Introduction: Patients with von Willebrand disease (VWD) require administration of von Willebrand factor (VWF) concentrates peri-operatively. Concerns about FVIII accumulation after repetitive injections of a 1:1 ratio VWF/FVIII clotting factor...
5.
Ariens S, Huisman A, Kremer Hovinga I, Urbanus R, van Galen K, van Vulpen L, et al.
Haemophilia
. 2024 May;
30(4):998-1002.
PMID: 38812123
Introduction: In patients with an increased bleeding tendency, extensive diagnostic blood testing is often performed. When results of tier 1 assays of primary haemostasis are normal, protocols recommend additional testing...
6.
van der Zwet K, van Galen K, Evers A, Fischer K, Schutgens R, van Vulpen L
Res Pract Thromb Haemost
. 2024 May;
8(3):102399.
PMID: 38689620
Background: Von Willebrand disease (VWD) type 3 is characterized by a complete deficiency of von Willebrand factor (VWF), resulting in a severe bleeding phenotype. Treatment often requires administration of VWF...
7.
Atiq F, Blok R, van Kwawegen C, Doherty D, Lavin M, van der Bom J, et al.
Blood
. 2023 Dec;
143(14):1414-1424.
PMID: 38142407
There is significant ongoing debate regarding type 1 von Willebrand disease (VWD) defintion. Previous guidelines recommended patients with von Willebrand factor (VWF) levels <30 IU/dL be diagnosed type 1 VWD,...
8.
Van t Klooster S, de Vaan A, van Leeuwen J, Pekel L, van Rijn-van Kortenhof N, Engelen E, et al.
Res Pract Thromb Haemost
. 2023 Dec;
7(7):102229.
PMID: 38077824
Background: Heavy menstrual bleeding (HMB), self-reported by 37% of adolescents, can be the first sign of a bleeding disorder (BD) during adolescence. The Dutch general practitioner (GP) guideline demands laboratory...
9.
Al Arashi W, Romano L, Leebeek F, Kruip M, van Galen K, Turan O, et al.
J Thromb Haemost
. 2023 Oct;
22(1):126-139.
PMID: 37778511
Background: Although desmopressin (DDAVP) is an accessible and inexpensive hemostatic drug, its use in pregnancy is still debated due to safety uncertainties. Objectives: We aimed to review the safety and...
10.
Versloot O, Kemler E, Blokzijl J, Timmer M, Schuuring M, van Galen K, et al.
Haemophilia
. 2023 May;
29(4):1013-1023.
PMID: 37224272
Background: Improved treatment options for people with haemophilia (PWH) have increased the possibilities for sports participation, but the risk of sports-induced bleeding (SIB) is still considered considerable by many. Aim:...